Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9

Journal of the American College of Cardiology

Volumn 59, Issue 19, 2012, Pages 1697-1705

  Melone, Michelle ^a   Wilsie, Larissa ^b   Palyha, Oksana ^b   Strack, Alison ^b   Rashid, Shirya ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

dyslipidemia; hepatic; LDL receptor; obesity; resistin

Indexed keywords

ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; KEXIN TYPE 9 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MEVINOLIN; RESISTIN; SERINE PROTEINASE; SUBTILISIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL; LYSOSOME; MALE; MOLECULAR MECHANICS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNOPRECIPITATION; LOVASTATIN; MODELS, BIOLOGICAL; OBESITY; PROPROTEIN CONVERTASES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LDL; RESISTIN; RNA, MESSENGER; SUBTILISIN;

EID: 84860465539     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.11.064     Document Type: Article

References (35)

1. World Health Organization World Health Organization Global Strategy on Diet, Physical Activity, and Health http://www.who.int/dietphysicalactivity/en Accessed March 21, 2012
2. S.M. Grundy Obesity, metabolic syndrome, and cardiovascular disease J Clin Endocrinol Metab 89 2004 2595 2600
3. J.P. Despres, I. Lemieux Abdominal obesity and metabolic syndrome Nature 444 2006 881 887
4. C.S. Fox, J.M. Massaro, U. Hoffmann Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study Circulation 116 2007 39 48
5. K. Musunuru Atherogenic dyslipidemia: cardiovascular risk and dietary intervention Lipids 45 2010 907 914
6. R.S. Rosenson Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities Curr Opin Cardiol 20 2005 313 317
7. A. Sniderman, P. Couture, J. de Graaf Diagnosis and treatment of apolipoprotein B dyslipoproteinemias Nat Rev Endocrinol 6 2010 335 346
8. M.J. Chapman, J.S. Redfern, M.E. McGovern, P. Giral Optimal pharmacotherapy to combat the atherogenic lipid triad Curr Opin Cardiol 26 2011 403 411
9. H.R. Superko, R.R. Gadesam Is it LDL particle size or number that correlates with risk for cardiovascular disease? Curr Atheroscler Rep 10 2008 377 385
10. R.S. Rosenson Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia Atherosclerosis 185 2006 327 330
11. K.J. Williams, I. Tabas Letter by Williams and Tabas regarding article "atherosclerosis 2005: recent discoveries and novel hypotheses." Circulation 113 2006 e782
12. D.C. Chan, G.F. Watts, T.G. Redgrave, T.A. Mori, P.H. Barrett Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration Metabolism 51 2002 1041 1046
13. M.S. Brown, J.L. Goldstein Biomedicine Lowering LDL - not only how low, but how long? Science 311 2006 1721 1723
14. A.D. Attie, N.G. Seidah Dual regulation of the LDL receptor - some clarity and new questions Cell Metab 1 2005 290 292
15. J.C. Mamo, G.F. Watts, P.H. Barrett, D. Smith, A.P. James, S. Pal Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab 281 2001 E626 E632
16. M.R. Flock, M.H. Green, P.M. Kris-Etherton Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol Adv Nutr 2 2011 261 274
17. P.G. McTernan, C.M. Kusminski, S. Kumar Resistin Curr Opin Lipidol 17 2006 170 175
18. M. Degawa-Yamauchi, J.E. Bovenkerk, B.E. Juliar Serum resistin (FIZZ3) protein is increased in obese humans J Clin Endocrinol Metab 88 2003 5452 5455
19. K. Piestrzeniewicz, K. Luczak, J. Komorowski, M. Maciejewski, W.J. Jankiewicz, J.H. Goch Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction Metabolism 57 2008 488 493
20. M. Yannakoulia, N. Yiannakouris, S. Bluher, A.L. Matalas, D. Klimis-Zacas, C.S. Mantzoros Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans J Clin Endocrinol Metab 88 2003 1730 1736
21. T.E. Jones, J.L. Basilio, P.M. Brophy, M.R. McCammon, R.C. Hickner Long-term exercise training in overweight adolescents improves plasma peptide YY and resistin Obesity (Silver Spring) 17 2009 1189 1195
22. S. Balducci, S. Zanuso, A. Nicolucci Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss Nutr Metab Cardiovasc Dis 20 2010 608 617
23. S. Bhutani, M.C. Klempel, R.A. Berger, K.A. Varady Improvements in coronary heart disease risk indicators by alternate-day fasting involve adipose tissue modulations Obesity (Silver Spring) 18 2010 2152 2159
24. M.P. Reilly, M. Lehrke, M.L. Wolfe, A. Rohatgi, M.A. Lazar, D.J. Rader Resistin is an inflammatory marker of atherosclerosis in humans Circulation 111 2005 932 939
25. H.E. Bays, J.M. Gonzalez-Campoy, G.A. Bray Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity Expert Rev Cardiovasc Ther 6 2008 343 368
26. N.M. Borradaile, L.E. de Dreu, P.H. Barrett, C.D. Behrsin, M.W. Huff Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation Biochemistry 42 2003 1283 1291
27. M. Owecki, E. Nikisch, A. Miczke, D. Pupek-Musialik, J. Sowinski Serum resistin is related to plasma HDL cholesterol and inversely correlated with LDL cholesterol in diabetic and obese humans Neuro Endocrinol Lett 31 2010 673 678
28. D.A. de Luis, M.G. Sagrado, R. Conde Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naive diabetes obese patients Diabetes Res Clin Pract 89 2010 110 114
29. S. Rashid, D.E. Curtis, R. Garuti Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proc Natl Acad Sci U S A 102 2005 5374 5379
30. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
31. B.J. Quilliam, H.E. Perez, V. Andros, P. Jones Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy J Manag Care Pharm 10 2004 244 250
32. G.L. Vega, S.M. Grundy Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men Am J Cardiol 81 1998 36B 42B
33. G.B. Kudolo, P. Bressler, R.A. DeFronzo Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment J Lipid Mediat Cell Signal 17 1997 97 113
34. E.J. Rhee A retrospective study on the efficacy of a ten-milligram dosage of atorvastatin for treatment of hypercholesterolemia in type 2 diabetes mellitus patients Diabetes Metab J 35 2011 86 87
35. E.N. Hampton, M.W. Knuth, J. Li, J.L. Harris, S.A. Lesley, G. Spraggon The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain Proc Natl Acad Sci U S A 104 2007 14604 14609